Department of Population Science and Medical Statistics, Faculty of Medicine, University of Southampton, C level, South Academic block, Southampton, Hampshire, UK.
Faculty of Medicine, University of Southampton, E level, South Academic block, Southampton, Hampshire, UK.
Harm Reduct J. 2017 Jul 11;14(1):44. doi: 10.1186/s12954-017-0172-z.
New, more effective and better-tolerated therapies for hepatitis C (HCV) have made the elimination of HCV a feasible objective. However, for this to be achieved, it is necessary to have a detailed understanding of HCV epidemiology in people who inject drugs (PWID). Respondent-driven sampling (RDS) can provide prevalence estimates in hidden populations such as PWID. The aims of this systematic review are to identify published studies that use RDS in PWID to measure the prevalence of HCV, and compare each study against the STROBE-RDS checklist to assess their sensitivity to the theoretical assumptions underlying RDS.
Searches were undertaken in accordance with PRISMA systematic review guidelines. Included studies were English language publications in peer-reviewed journals, which reported the use of RDS to recruit PWID to an HCV bio-behavioural survey. Data was extracted under three headings: (1) survey overview, (2) survey outcomes, and (3) reporting against selected STROBE-RDS criteria.
Thirty-one studies met the inclusion criteria. They varied in scale (range 1-15 survey sites) and the sample sizes achieved (range 81-1000 per survey site) but were consistent in describing the use of standard RDS methods including: seeds, coupons and recruitment incentives. Twenty-seven studies (87%) either calculated or reported the intention to calculate population prevalence estimates for HCV and two used RDS data to calculate the total population size of PWID. Detailed operational and analytical procedures and reporting against selected criteria from the STROBE-RDS checklist varied between studies. There were widespread indications that sampling did not meet the assumptions underlying RDS, which led to two studies being unable to report an estimated HCV population prevalence in at least one survey location.
RDS can be used to estimate a population prevalence of HCV in PWID and estimate the PWID population size. Accordingly, as a single instrument, it is a useful tool for guiding HCV elimination. However, future studies should report the operational conduct of each survey in accordance with the STROBE-RDS checklist to indicate sensitivity to the theoretical assumptions underlying the method.
PROSPERO CRD42015019245.
新型、更有效和耐受性更好的丙型肝炎(HCV)疗法使消除 HCV 成为可能。然而,要实现这一目标,就必须深入了解注射吸毒者(PWID)中的 HCV 流行病学。回应驱动抽样(RDS)可以为 PWID 等隐蔽人群提供患病率估计。本系统综述的目的是确定使用 RDS 测量 PWID 中 HCV 患病率的已发表研究,并根据 STROBE-RDS 清单对每项研究进行比较,以评估其对 RDS 理论假设的敏感性。
按照 PRISMA 系统综述指南进行搜索。纳入的研究为在同行评议期刊上发表的英文出版物,报告了使用 RDS 招募 PWID 参加 HCV 生物行为调查。数据分为三个标题提取:(1)调查概述,(2)调查结果,(3)根据选定的 STROBE-RDS 标准报告。
符合纳入标准的研究有 31 项。它们在规模(调查地点范围为 1-15 个)和实现的样本量(每个调查地点 81-1000 人)上有所不同,但都一致描述了使用标准 RDS 方法,包括:种子、优惠券和招募激励。27 项研究(87%)计算或报告了 HCV 人群患病率估计的意图,两项研究使用 RDS 数据计算了 PWID 的总人口规模。研究之间详细的操作和分析程序以及对 STROBE-RDS 清单选定标准的报告差异很大。有广泛的迹象表明,抽样不符合 RDS 背后的假设,这导致两项研究在至少一个调查地点无法报告估计的 HCV 人群患病率。
RDS 可用于估计 PWID 中 HCV 的人群患病率,并估计 PWID 人口规模。因此,作为一种单一工具,它是指导 HCV 消除的有用工具。然而,未来的研究应按照 STROBE-RDS 清单报告每个调查的操作过程,以表明对该方法理论假设的敏感性。
PROSPERO CRD42015019245。